CancerFax

14/05/2026

Shout out to our newest followers! Excited to have you onboard! Louise Karasiak, Toni Marie, Michael Wellendorf, Muhammad Shoaib Hashmi

08/05/2026

Today is World Thalassemia Day.

For decades, transfusion-dependent beta-thalassemia has meant a lifetime of monthly transfusions, iron chelation, and the constant management of complications. For many families, especially across India, South Asia, the MENA region, and the CIS, it has meant building life around the rhythm of the transfusion clinic.

That picture is finally changing.
Two gene therapies for transfusion-dependent beta-thalassemia are now approved internationally. For eligible , they offer the possibility of transfusion independence after a single . The that took thirty years to mature is here.

The remaining problem is access.
Current pricing places these therapies out of reach for almost every family in the regions where the disease burden is highest. The infrastructure to deliver them, cell processing, lentiviral vector supply, conditioning protocols, and long-term follow-up exists in only a handful of centers worldwide.

Closing that gap is the work that matters now.

Localization of manufacturing. transfer to high-burden countries. Regulatory pathways that move at the pace patients need. Hospital readiness for cell and gene therapy delivery. Pricing structures that reflect the populations being served.

CancerFax works alongside families navigating advanced hematologic conditions, including transfusion-dependent thalassemia, sickle cell disease, and related disorders. We help patients understand their options, access second opinions from leading hematology centers, evaluate eligibility for advanced therapies and clinical trials, and coordinate cross-border care where required.

If you are a family seeking guidance, a clinician with a complex case, or a partner working on access pathways for hematologic diseases, we would like to hear from you.

Patient services: [email protected] WhatsApp / WeChat: +86 182 1759 2149

03/05/2026

A 54-year-old woman from Eastern Europe was told her metastatic breast cancer had no further options.

When her file came to us, three things stood out:

1. She had never had comprehensive genomic profiling
2. Her HER2 status had only been tested by IHC, never by FISH or NGS
3. Her oncologist hadn't considered HER2-low classification, a category that opens up trastuzumab deruxtecan and changes the entire treatment conversation

We weren't doing anything magical. We were doing what a precision oncology workup should have done at diagnosis.

This is the gap that kills people.

Not the absence of treatment.

The absence of someone asking the right questions early enough.

If you're a patient or caregiver reading this , comprehensive genomic profiling at diagnosis is no longer optional in advanced cancer. It's the single most important predictor of whether you'll find the right therapy.

30/04/2026

CancerFax is a global cancer access platform.

We help international patients reach advanced treatments, clinical trials, and second opinions across the US, India, China, and beyond.

What we do:
→ Clinical case review by qualified medical staff (PhD Biotech, PharmD)
→ International treatment navigation across 4 continents
→ Access to clinical trials and advanced therapies — CAR-T, oncolytic viruses, gene therapies, precision oncology
→ Cross-border coordination from diagnosis to follow-up

Who we serve:

Patients, families, and referring physicians who need clarity in some of the most difficult decisions of their lives.

Follow this page for clinical insights, treatment landscape updates, and what's actually happening in global cancer care.

28/04/2026

Most international cancer patients don't lose because their disease is untreatable.

They lose because nobody helped them find the right treatment in time.

I've spent years watching patients from CIS countries, the Middle East, and Southeast Asia navigate an impossible maze:

— A pathology report in Russian that no one translates clinically
— A genomic test ordered but never explained
— A trial in Boston they qualify for but never hear about
— A therapy in Shanghai that could change their trajectory but feels out of reach

CancerFax exists for this gap.

Not as a medical tourism agency. Not as a hospital broker.

As a global cancer access platform, built around clinical seriousness, international navigation, and treatment options patients most never even know exist.

We're a small team. We won't be the loudest voice in oncology. But we intend to be one of the most trusted.

If you're an oncologist, hospital partner, or researcher working on advanced therapies, we would like to know you.



Picture: Radiation room of one of our partner hospitals in Beijing, China.

08/04/2026

CAR-T therapy is one of the most talked-about advances in cancer treatment, but it is also one of the most misunderstood.

It is not a general treatment for every cancer.
It is not a magic solution.
And it is not suitable for every patient.

But in the right case, under the right team, it can be a very important option to evaluate.

The most important thing families need is not hype. It is understanding.

Save this post if you want more simple breakdowns of advanced cancer treatments.

Comment CAR-T if you want us to do a post on who may be considered for it.

06/04/2026

06/04/2026

When a family hears the word "cancer," the next few days often become a blur of fear, urgency, confusion, and rushed decisions.

That is precisely why CancerFax exists.

We help patients and families understand advanced treatment options, explore second opinions, and access global cancer care pathways when local options feel limited, unclear, or exhausted.

We are not here to create false hope. We are here to create clarity.
Because in cancer care, the right information at the right time can change everything.

Follow CancerFax for clear, compassionate, science-led guidance on advanced cancer treatment options.

Comment GUIDE if you want us to create more content on what families should do first after diagnosis.

04/04/2026

India’s oncology NGS market is projected to grow at 17%+ CAGR through 2030.

But what does that number actually mean for practising oncologists?
Here’s the landscape:
• India sees over 14 lakh new cancer cases annually. Rising.
• Only a small fraction currently receives comprehensive genomic profiling.
• The market had just 2–3 NGS players in 2015. Today, there are 13–14 providers.
• Sequencing costs have dropped dramatically, making NGS increasingly feasible.
• Government initiatives like dbGENVOC and the Union Budget 2025–26 for cancer care provisions are building the infrastructure.

But here’s the gap:

Metro cities still heavily concentrate on NGS adoption. Limited access to NGS is available in Tier-2 and Tier-3 centers, where a significant proportion of cancer patients receive treatment.

The technology is ready. The guidelines support it. The market is growing.

The question now is, how do we bridge the last mile?
That’s a question we think about every day at CancerFax. And we’d love to hear your perspective.

29/03/2026

🚀 Exciting News in Cancer Treatment! 🚀

The FDA has now approved Hernexeos (zongertinib) as the first treatment option for adults with HER2-Mutant non-small cell lung cancer. This breakthrough means that 76% of patients saw their tumors shrink, offering new hope and improved outcomes for many.

Stay informed with CancerFax Insights, your trusted source for the latest in cancer care and oncology.

Read more about this significant advancement here: https://cancerfax.beehiiv.com/p/fda-expands-approval-of-hernexeos-for-first-line-her2-mutant-lung-cancer-76-of-patients-saw-tumors-s